domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15*
+
+Value in Health peer-reviewed modeling study (2025) projects Medicare saves $715M over 10 years from comprehensive semaglutide access across T2D, obesity, and MASH indications. The study models 38,950 CV events avoided and 6,180 deaths prevented, with T2D-related savings of $892M exceeding obesity-related costs of $205M. This challenges the 'inflationary through 2035' framing by demonstrating that for risk-bearing payers who capture both drug costs and downstream savings, GLP-1s can be cost-saving. The distinction is structural: system-level analysis (which supports the inflationary claim) distributes savings across fragmented payers, while integrated payer analysis (Medicare, MA plans) internalizes the prevention ROI.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15*
+
+Value in Health Medicare modeling quantifies the multi-organ value: per subject, semaglutide generates $14,431 in avoided T2D costs, $2,074 in avoided CKD costs, and $1,512 in avoided CV event costs. Per 100,000 subjects treated over 10 years: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided. The MASH savings are modest ($28M total) despite clinical efficacy, suggesting the 10-year window doesn't capture enough MASH progression costs to generate large offsets. The compounding value is real and quantifiable when a single payer bears both costs and savings.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15*
+
+Value in Health Medicare modeling confirms CKD savings at $2,074 per subject treated, contributing to the $715M net savings over 10 years. While this is smaller than the T2D-related savings ($14,431/subject), it represents substantial value from a single indication. The study validates that kidney disease progression delay translates to measurable cost offsets when the payer bears both treatment and complication costs.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -29,6 +29,12 @@ PACE represents the extreme end of value-based care alignment—100% capitation
 
 GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-15*
+
+The Medicare semaglutide savings analysis provides a concrete example of why full-risk arrangements produce different outcomes than partial-risk arrangements: Medicare's ability to save $715M over 10 years depends on bearing both drug costs ($47,353 average lifetime treatment cost per subject) and downstream savings from avoided complications. The 60% of payments that 'touch value metrics' without bearing full risk would not capture enough of the $18,017 per-subject savings (from avoided T2D, CKD, and CV costs) to justify the upfront drug investment. This demonstrates the payment boundary problem in action—prevention ROI requires the entity paying for prevention to also bear the cost of complications.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json

@@ -0,0 +1,34 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "value-based-care-payment-structures-enable-glp-1-cost-savings-that-fee-for-service-cannot-capture-because-capitated-risk-aligns-drug-costs-with-downstream-savings.md",
+      "issues": [
+        "missing_attribution_extractor",
+        "opsec_internal_deal_terms"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md:set_created:2026-03-15",
+      "value-based-care-payment-structures-enable-glp-1-cost-savings-that-fee-for-service-cannot-capture-because-capitated-risk-aligns-drug-costs-with-downstream-savings.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-cardiovascular-and-metabolic-benefits-offset-drug-costs-when-single-payer-bears-both-costs-and-savings.md:missing_attribution_extractor",
+      "value-based-care-payment-structures-enable-glp-1-cost-savings-that-fee-for-service-cannot-capture-because-capitated-risk-aligns-drug-costs-with-downstream-savings.md:missing_attribution_extractor",
+      "value-based-care-payment-structures-enable-glp-1-cost-savings-that-fee-for-service-cannot-capture-because-capitated-risk-aligns-drug-costs-with-downstream-savings.md:opsec_internal_deal_terms"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,17 @@ Key findings:
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
 EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
+
+
+## Key Facts
+- Medicare semaglutide modeling projects net savings of $715M over 10 years (range: $412M to $1.04B)
+- 38,950 cardiovascular events avoided over 10 years in Medicare population
+- 6,180 deaths avoided (CV events + CKD/MASH progression)
+- T2D-related savings: ~$892 million over 10 years
+- Obesity-related costs: ~$205 million over 10 years
+- MASH-related savings: ~$28 million over 10 years
+- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime treatment costs: $47,353
+- Savings from avoided T2D: $14,431/subject
+- Savings from avoided CKD: $2,074/subject
+- Savings from avoided CV events: $1,512/subject